Assertio Therapeutics Announces Completion and Final Results of the Offer to Purchase All of Its Issued and Outstanding 2.50%...
April 08 2020 - 4:05PM
Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ:
ASRT), today announced the completion and final results for its
cash tender offers (the “Offers”) to purchase any and all of the
outstanding $42,465,000 in aggregate principal amount of its 2.50%
Senior Convertible Notes due 2021 (CUSIP: 249908AA2) (“2021 Notes”)
and $34,522,000 of its 5.00% Senior Convertible Notes due 2024
(CUSIP: 04545LAA5) (“2024 Notes”, together with the 2021 Notes, the
“Notes”).
The Offers were made on the terms and subject to the conditions
set forth in an Offer to Purchase dated March 11, 2020 (the “Offer
to Purchase”) and expired at 11:59 p.m., New York City time, on
April 7, 2020 (the “Expiration Time”). As of the Expiration Time of
the Offers, $42,130,000 aggregate principal of 2021 Notes and
$34,522,000 aggregate principal of 2024 Notes have been validly
tendered and not validly withdrawn (the “Accepted Notes”). Holders
of the Accepted Notes are entitled to receive in cash $995 per
$1,000 principal amount of Accepted Notes, plus accrued and unpaid
interest on such Notes up to, but not including, the date the
Offers are settled, which is expected to be April 9, 2020.
To help facilitate the Offers, Assertio retained SunTrust
Robinson Humphrey, Inc. to act as dealer manager and Global
Bondholder Services Corporation to act as information and tender
agent. Holders of Notes who have questions may contact Global
Bondholder Services Corporation by telephone at (866) 807-2200
(toll-free in North America) or by email at contact@gbsc-usa.com or
SunTrust Robinson Humphrey, Inc. at (404) 926-5675.
This news release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. In any jurisdiction in which the securities laws or
blue sky laws require the Offers to be made by a licensed broker or
dealer, the Offers will be deemed to be made on behalf of the
Company by one or more registered brokers or dealers that are
licensed under the laws of such jurisdiction.
About Assertio Therapeutics, Inc. Assertio
Therapeutics is committed to providing responsible solutions to
advance patient care in the Company’s core areas of neurology,
orphan and specialty medicines. Assertio currently markets two
FDA-approved products and continues to identify, license and
develop new products that offer enhanced options for patients that
may be underserved by existing therapies. To learn more about
Assertio, visit www.assertiotx.com.
"Safe Harbor" Statement Under the
Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements. Words
such as "anticipates," "estimates," "expects," "projects,"
"forecasts," "intends," "plans," "will," "believes" and words and
terms of similar substance used in connection with any discussion
identify forward-looking statements. These forward-looking
statements are based on management's current expectations and
beliefs about future events and are inherently susceptible to
uncertainty and changes in circumstance These statements involve
inherent risks and uncertainties that could cause actual results to
differ materially from those projected or anticipated, including
risks related to the proposed purchase transactions and other risks
outlined in Assertio’s public filings with the Securities and
Exchange Commission, including Assertio’s most recent annual report
on Form 10-K. All information provided in this news release speaks
as of the date hereof. Except as otherwise required by law,
Assertio undertakes no obligation to update or revise its
forward-looking statements.
Investor and Media Contact: Dan Peisert Senior
Vice President and Chief Financial
Officerdpeisert@assertiotx.com
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From Sep 2023 to Sep 2024